386 related articles for article (PubMed ID: 25367684)
21. Interleukin-33 overexpression reflects less aggressive tumour features in large-duct type cholangiocarcinomas.
Sawada R; Ku Y; Akita M; Otani K; Fujikura K; Itoh T; Ajiki T; Fukumoto T; Kakeji Y; Zen Y
Histopathology; 2018 Aug; 73(2):259-272. PubMed ID: 29675965
[TBL] [Abstract][Full Text] [Related]
22. Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features.
Liau JY; Tsai JH; Yuan RH; Chang CN; Lee HJ; Jeng YM
Mod Pathol; 2014 Aug; 27(8):1163-73. PubMed ID: 24406866
[TBL] [Abstract][Full Text] [Related]
23. Comparative clinicopathological study of biliary intraductal papillary neoplasms and papillary cholangiocarcinomas.
Fujikura K; Fukumoto T; Ajiki T; Otani K; Kanzawa M; Akita M; Kido M; Ku Y; Itoh T; Zen Y
Histopathology; 2016 Dec; 69(6):950-961. PubMed ID: 27410028
[TBL] [Abstract][Full Text] [Related]
24. CA9 overexpression is an independent favorable prognostic marker in intrahepatic cholangiocarcinoma.
Gu M
Int J Clin Exp Pathol; 2015; 8(1):862-6. PubMed ID: 25755787
[TBL] [Abstract][Full Text] [Related]
25. High-mobility group box 1 expression and lymph node metastasis in intrahepatic cholangiocarcinoma.
Xu YF; Ge FJ; Han B; Yang XQ; Su H; Zhao AC; Zhao MH; Yang YB; Yang J
World J Gastroenterol; 2015 Mar; 21(11):3256-65. PubMed ID: 25805932
[TBL] [Abstract][Full Text] [Related]
26. Intrahepatic clear cell cholangiocarcinoma: immunohistochemical aspects in a very rare type of cholangiocarcinoma.
Haas S; Gütgemann I; Wolff M; Fischer HP
Am J Surg Pathol; 2007 Jun; 31(6):902-6. PubMed ID: 17527078
[TBL] [Abstract][Full Text] [Related]
27. Sox9 expression in carcinogenesis and its clinical significance in intrahepatic cholangiocarcinoma.
Matsushima H; Kuroki T; Kitasato A; Adachi T; Tanaka T; Hirabaru M; Hirayama T; Kuroshima N; Hidaka M; Soyama A; Takatsuki M; Kinoshita N; Sano K; Nishida N; Eguchi S
Dig Liver Dis; 2015 Dec; 47(12):1067-75. PubMed ID: 26341967
[TBL] [Abstract][Full Text] [Related]
28. Altered mucin gene expression in stone-containing intrahepatic bile ducts and cholangiocarcinomas.
Lee KT; Liu TS
Dig Dis Sci; 2001 Oct; 46(10):2166-72. PubMed ID: 11680592
[TBL] [Abstract][Full Text] [Related]
29. Epithelial-mesenchymal transition phenotypes are associated with patient survival in intrahepatic cholangiocarcinoma.
Gu MJ; Choi JH
J Clin Pathol; 2014 Mar; 67(3):229-34. PubMed ID: 24062361
[TBL] [Abstract][Full Text] [Related]
30. Differential expression of the anterior gradient protein-2 is a conserved feature during morphogenesis and carcinogenesis of the biliary tree.
Lepreux S; Bioulac-Sage P; Chevet E
Liver Int; 2011 Mar; 31(3):322-8. PubMed ID: 21281432
[TBL] [Abstract][Full Text] [Related]
31. Bile duct expression of pancreatic and duodenal homeobox 1 in perihilar cholangiocarcinogenesis.
Igarashi S; Matsubara T; Harada K; Ikeda H; Sato Y; Sasaki M; Matsui O; Nakanuma Y
Histopathology; 2012 Aug; 61(2):266-76. PubMed ID: 22594685
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of epithelial-mesenchymal transition-related markers according to cell dedifferentiation: clinical implications as an independent predictor of poor prognosis in cholangiocarcinoma.
Ryu HS; Chung JH; Lee K; Shin E; Jing J; Choe G; Kim H; Xu X; Lee HE; Kim DG; Lee H; Jang JJ
Hum Pathol; 2012 Dec; 43(12):2360-70. PubMed ID: 23084587
[TBL] [Abstract][Full Text] [Related]
33. Glycine N-methyltransferase is a favorable prognostic marker for human cholangiocarcinoma.
Huang YC; Chen M; Shyr YM; Su CH; Chen CK; Li AF; Ho DM; Chen YM
J Gastroenterol Hepatol; 2008 Sep; 23(9):1384-9. PubMed ID: 18624901
[TBL] [Abstract][Full Text] [Related]
34. BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma.
Goeppert B; Frauenschuh L; Renner M; Roessler S; Stenzinger A; Klauschen F; Warth A; Vogel MN; Mehrabi A; Hafezi M; Boehmer K; von Deimling A; Schirmacher P; Weichert W; Capper D
Mod Pathol; 2014 Jul; 27(7):1028-34. PubMed ID: 24309328
[TBL] [Abstract][Full Text] [Related]
35. Expression and prognostic value of PRL-3 in human intrahepatic cholangiocarcinoma.
Xu Y; Zhu M; Zhang S; Liu H; Li T; Qin C
Pathol Oncol Res; 2010 Jun; 16(2):169-75. PubMed ID: 19757198
[TBL] [Abstract][Full Text] [Related]
36. Regulators of apoptosis in cholangiocarcinoma.
Jhala NC; Vickers SM; Argani P; McDonald JM
Arch Pathol Lab Med; 2005 Apr; 129(4):481-6. PubMed ID: 15794670
[TBL] [Abstract][Full Text] [Related]
37. Expression of blood group-related antigens in cholangiocarcinoma in relation to non-neoplastic bile ducts.
Minato H; Nakanuma Y; Terada T
Histopathology; 1996 May; 28(5):411-9. PubMed ID: 8735716
[TBL] [Abstract][Full Text] [Related]
38. ZEB1 expression is associated with prognosis of intrahepatic cholangiocarcinoma.
Terashita K; Chuma M; Hatanaka Y; Hatanaka K; Mitsuhashi T; Yokoo H; Ohmura T; Ishizu H; Muraoka S; Nagasaka A; Tsuji T; Yamamoto Y; Kurauchi N; Shimoyama N; Toyoda H; Kumada T; Kaneoka Y; Maeda A; Ogawa K; Natsuizaka M; Kamachi H; Kakisaka T; Kamiyama T; Taketomi A; Matsuno Y; Sakamoto N
J Clin Pathol; 2016 Jul; 69(7):593-9. PubMed ID: 26670746
[TBL] [Abstract][Full Text] [Related]
39. Liver fluke-associated and sporadic cholangiocarcinoma: an immunohistochemical study of bile duct, peribiliary gland and tumour cell phenotypes.
Hughes NR; Pairojkul C; Royce SG; Clouston A; Bhathal PS
J Clin Pathol; 2006 Oct; 59(10):1073-8. PubMed ID: 16679351
[TBL] [Abstract][Full Text] [Related]
40. Intrahepatic cholangiocarcinoma frequently shows loss of BAP1 and PBRM1 expression, and demonstrates specific clinicopathological and genetic characteristics with BAP1 loss.
Misumi K; Hayashi A; Shibahara J; Arita J; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M
Histopathology; 2017 Apr; 70(5):766-774. PubMed ID: 27864835
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
